Mediators of cognitive impairment in cerebral amyloid angiopathy.


Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
01 2023
Historique:
pubmed: 28 4 2022
medline: 30 12 2022
entrez: 27 4 2022
Statut: ppublish

Résumé

Cerebral amyloid angiopathy (CAA) is associated with cognitive decline. CAA has diverse impacts on brain structure and function; however, the brain lesions that mediate the association of CAA with cognition are not understood well. To determine the degree to which CAA neuroimaging biomarkers mediate the association of CAA with cognitive dysfunction. We analyzed cross-sectional data of patients with probable CAA and controls without cognitive impairment from the Functional Assessment of Vascular Reactivity study. Neuropsychological tests were grouped into domains of memory, executive function, and processing speed. Candidate CAA neuroimaging biomarkers were pre-specified based on prior literature, consisting of white matter hyperintensity volume, peak width of skeletonized mean diffusivity (PSMD) on diffusion tensor magnetic resonance imaging (MRI), cerebrovascular reactivity (CVR), cortical thickness, and cortical thickness in a meta-region of interest typically affected by Alzheimer's disease (AD). Cognitive scores and neuroimaging markers were standardized and reported in relation to values in controls. Mediation analysis was used to estimate the total effect of CAA on cognition and the proportion of the total effect that was mediated by neuroimaging biomarkers, controlling for age, sex, and education. There were 131 participants (67 CAA and 64 controls). Mean age was 72.1 ± 7.7 years, and 54.2% were women. As expected, compared to controls, CAA was associated with lower cognition. In mediation analyses, CAA had direct unmediated effects of 48%, 46%, and 52% on all three cognitive domains. The association of CAA with memory was partially mediated by CVR and PSMD, accounting for 18% and 36% of the total effect of CAA. The association of CAA with executive function was partially mediated by PSMD and mean cortical thickness in the AD meta-region of interest (ROI), accounting for 33% and 31% of the total effect of CAA. The association of CAA with processing speed was partially mediated by CVR and PSMD, accounting for 8% and 34% of the total effect of CAA. Among CAA participants, the presence of cortical superficial siderosis was associated with lower processing speed. Altered white matter diffusivity (i.e. PSMD), CVR, and atrophy, taken together, account for about half the effect of CAA on cognition.

Sections du résumé

BACKGROUND
Cerebral amyloid angiopathy (CAA) is associated with cognitive decline. CAA has diverse impacts on brain structure and function; however, the brain lesions that mediate the association of CAA with cognition are not understood well.
AIMS
To determine the degree to which CAA neuroimaging biomarkers mediate the association of CAA with cognitive dysfunction.
METHODS
We analyzed cross-sectional data of patients with probable CAA and controls without cognitive impairment from the Functional Assessment of Vascular Reactivity study. Neuropsychological tests were grouped into domains of memory, executive function, and processing speed. Candidate CAA neuroimaging biomarkers were pre-specified based on prior literature, consisting of white matter hyperintensity volume, peak width of skeletonized mean diffusivity (PSMD) on diffusion tensor magnetic resonance imaging (MRI), cerebrovascular reactivity (CVR), cortical thickness, and cortical thickness in a meta-region of interest typically affected by Alzheimer's disease (AD). Cognitive scores and neuroimaging markers were standardized and reported in relation to values in controls. Mediation analysis was used to estimate the total effect of CAA on cognition and the proportion of the total effect that was mediated by neuroimaging biomarkers, controlling for age, sex, and education.
RESULTS
There were 131 participants (67 CAA and 64 controls). Mean age was 72.1 ± 7.7 years, and 54.2% were women. As expected, compared to controls, CAA was associated with lower cognition. In mediation analyses, CAA had direct unmediated effects of 48%, 46%, and 52% on all three cognitive domains. The association of CAA with memory was partially mediated by CVR and PSMD, accounting for 18% and 36% of the total effect of CAA. The association of CAA with executive function was partially mediated by PSMD and mean cortical thickness in the AD meta-region of interest (ROI), accounting for 33% and 31% of the total effect of CAA. The association of CAA with processing speed was partially mediated by CVR and PSMD, accounting for 8% and 34% of the total effect of CAA. Among CAA participants, the presence of cortical superficial siderosis was associated with lower processing speed.
CONCLUSION
Altered white matter diffusivity (i.e. PSMD), CVR, and atrophy, taken together, account for about half the effect of CAA on cognition.

Identifiants

pubmed: 35473418
doi: 10.1177/17474930221099352
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

78-84

Subventions

Organisme : CIHR
ID : MOP-142175
Pays : Canada
Organisme : CIHR
ID : FDN-154317
Pays : Canada

Auteurs

Romella Durrani (R)

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.

Meng Wang (M)

Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.

Emily Cox (E)

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.

Elisabeth Irving (E)

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.

Feryal Saad (F)

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.

Cheryl R McCreary (CR)

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
Department of Radiology, University of Calgary, Calgary, AB, Canada.

Andrew E Beaudin (AE)

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
Hotchkiss Brain Institute, Calgary, AB, Canada.

Myrlene Gee (M)

Department of Radiology, University of Calgary, Calgary, AB, Canada.

Krista Nelles (K)

Department of Radiology, University of Calgary, Calgary, AB, Canada.

Tolulope T Sajobi (TT)

Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
Hotchkiss Brain Institute, Calgary, AB, Canada.

Zahinoor Ismail (Z)

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
Hotchkiss Brain Institute, Calgary, AB, Canada.
Department of Psychiatry, University of Calgary, Calgary, AB, Canada.

Richard Camicioli (R)

Department of Medicine, Division of Neurology and Neuroscience and Mental Health Institute (NMHI), University of Alberta, Edmonton, AB, Canada.

Eric E Smith (EE)

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
Department of Radiology, University of Calgary, Calgary, AB, Canada.
Hotchkiss Brain Institute, Calgary, AB, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH